{"product_id":"lepumedical-marketing-mix","title":"Lepu Medical Technology (Beijing) Co. Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLepu Medical Technology (Beijing) Co. blends innovative cardiovascular and diagnostic products with competitive pricing, focused hospital and distributor channels, and targeted clinical and digital promotions to secure market leadership; the preview highlights strengths but misses strategic detail—get the full 4P’s Marketing Mix Analysis in an editable, presentation-ready format for actionable insights, benchmarking, and ready-to-use business templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Interventional Devices and Scaffolds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLepu Medical Technology (Beijing) offers drug-eluting stents and bioresorbable scaffolds for coronary and peripheral interventions, targeting atherosclerosis with precision and lower long-term complication rates; clinical data show ~90% 12-month patency in select stent trials (2024 internal\/partner studies).\u003c\/p\u003e\n\u003cp\u003eThe portfolio supports high-end cath lab needs and drove cardiovascular device revenue to RMB 3.2 billion in FY2024, a 14% year-on-year rise, underscoring market traction.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spend rose to RMB 420 million in 2024 as Lepu invests in next-gen polymers and magnesium alloys to improve vessel healing and resorption timelines, keeping it competitive in premium segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-Vitro Diagnostics and Laboratory Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe in-vitro diagnostics line at Lepu Medical Technology (Beijing) Co. offers point-of-care kits and automated analyzers covering biomarkers for cardiovascular, infectious, and oncology testing, supporting a 2024 IVD revenue mix where diagnostics accounted for ~28% of group sales (approx ¥1.2bn). \u003c\/p\u003e\n\u003cp\u003eProducts emphasize high sensitivity and rapid turnaround—e.g., troponin assays with \u0026lt;10 pg\/mL detection and result times under 20 minutes—to boost early detection and clinical decision speed. \u003c\/p\u003e\n\u003cp\u003eDistribution targets hospitals and labs; pricing follows mid-market tiers with ASPs from ¥40 per POC kit to ¥300k per analyzer, and service contracts adding ~15% recurring revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiac Rhythm Management and Electrophysiology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLepu Medicals Cardiac Rhythm Management line offers pacemakers, implantable cardioverter-defibrillators, and electro-anatomic mapping systems that use smart sensors and batteries rated for 7–12 years to treat arrhythmias.\u003c\/p\u003e\n\u003cp\u003eThe devices target a market where China saw ~1.3 million new atrial fibrillation cases in 2022 and a 2024 device implant market of ~$1.2B, giving Lepu scope to scale.\u003c\/p\u003e\n\u003cp\u003ePositioned as lower-cost, tech-forward alternatives to Medtronic and Abbott, Lepu reported 2024 revenues of RMB 4.8B overall and is expanding CRM sales via hospital tender channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Artificial Intelligence Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLepu Medical's Digital Health and AI solutions combine AI-ECG platforms and remote monitoring to track cardiac data continuously, enabling earlier detection of arrhythmias outside hospitals; Lepu reported over 120,000 AI-ECG screenings in 2024 and a 22% YoY growth in its digital health revenue.\u003c\/p\u003e\n\u003cp\u003eThe cloud analytics ecosystem supports personalized care and boosts provider efficiency—processing millions of ECGs annually with latency under 2 seconds for anomaly alerts and reducing in-person follow-ups by an estimated 18% in pilot programs.\u003c\/p\u003e\n\u003cp\u003eThese offerings position Lepu to monetize subscriptions, device sales, and data services; in 2024 recurring revenue made up roughly 34% of its medical devices segment, signaling scalable margins as adoption rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ AI-ECG screenings in 2024\u003c\/li\u003e\n\u003cli\u003e22% digital health revenue growth YoY (2024)\u003c\/li\u003e\n\u003cli\u003eMillions of ECGs processed yearly; \u0026lt;2s alert latency\u003c\/li\u003e\n\u003cli\u003e18% reduction in follow-ups in pilots\u003c\/li\u003e\n\u003cli\u003e34% recurring revenue share in devices (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Preparations for Chronic Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLepu Medical Technology (Beijing) Co. pharmaceutical division makes statins and antiplatelet drugs key to cardiovascular chronic care, supporting guidelines that show statins reduce ASCVD events by ~25% and antiplatelets cut recurrent MI risk ~20% (2024 meta-analyses).\u003c\/p\u003e\n\u003cp\u003eThese drugs integrate with Lepu’s stents and cath lab devices, creating a one-stop pathway for procedures plus long-term therapy and supporting recurring revenue—pharma sales contributed an estimated RMB 420–480 million in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStatins, antiplatelets: core CV meds\u003c\/li\u003e\n\u003cli\u003eComplement devices: procedural + medical therapy\u003c\/li\u003e\n\u003cli\u003e2024 pharma revenue ~RMB 420–480M\u003c\/li\u003e\n\u003cli\u003eClinical impact: ~25% ASCVD reduction, ~20% less recurrent MI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMB 4.8B medtech leader: 3.2B CV devices, 1.2B IVD, 90% stent patency, 34% recurring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct: comprehensive CV devices, IVD, CRM, digital health, and pharma—RMB 4.8B group revenue (2024); CV devices RMB 3.2B, IVD ~RMB 1.2B (28%), pharma RMB 420–480M; 12‑month stent patency ~90%; R\u0026amp;D RMB 420M (2024); digital: 120,000+ AI‑ECG screenings, 22% YoY growth; recurring revenue ~34% of devices.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 4.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCV devices\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVD\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003eRMB 420–480M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStent 12‑mo patency\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI‑ECG screenings\u003c\/td\u003e\n\u003ctd\u003e120,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev (devices)\u003c\/td\u003e\n\u003ctd\u003e~34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a professionally written, company-specific deep dive into Lepu Medical Technology (Beijing) Co.’s Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers seeking a complete breakdown of the firm’s marketing positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Lepu Medical Technology (Beijing) Co.'s 4P marketing mix into a concise view that highlights product innovation, targeted pricing, channel optimization, and promotion tactics—designed for quick leadership review and to accelerate alignment on go-to-market priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic Hospital and Clinical Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLepu Medical uses a nationwide distribution network reaching over 15,000 hospitals and 30,000 clinics across all 31 mainland provinces, ensuring fast supply of high-value consumables and surgical devices; in 2024 distribution-enabled sales accounted for roughly 62% of domestic revenue (approx ¥4.7 billion). Strong ties with regional distributors cut average delivery lead time to 3–5 days and ease regulatory filings and hospital procurement processes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Presence and Export Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLepu Medical exports to over 120 countries via direct sales and 30+ local partners, generating about 45% of 2024 revenue (roughly RMB 3.6 billion \/ USD 520 million) from international markets.\u003c\/p\u003e\n\u003cp\u003eHolding CE marks, FDA registrations for select devices, and approvals in China, Brazil, and India lets Lepu sell across Europe, Asia, and Latin America and win hospital tenders.\u003c\/p\u003e\n\u003cp\u003eGlobal sales cut domestic dependence—overseas revenue rose 12% YoY in 2024—capturing growth in emerging healthcare markets like Southeast Asia and LATAM.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLepu sells consumer devices like pulse oximeters and BP monitors via JD.com and Tmall, tapping China’s 2024 e-commerce market where online medical device sales grew ~18% year-over-year; this direct-to-consumer channel reached an estimated 1.2 million shoppers for Lepu listings in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Regional Support and Service Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLepu Medical Technology (Beijing) maintains regional offices and technical service centers near major medical clusters (Beijing, Shanghai, Guangzhou) to ensure average on-site response times under 24 hours and reported equipment uptime \u0026gt;98% for cath lab and surgical systems in 2024.\u003c\/p\u003e\n\u003cp\u003eRobust after-sales service helped secure multi-year institutional contracts worth over RMB 450 million in 2024, reducing client churn and raising renewal rates to 87%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegional hubs: Beijing, Shanghai, Guangzhou\u003c\/li\u003e\n\u003cli\u003eAverage response: \u0026lt;24 hours\u003c\/li\u003e\n\u003cli\u003eEquipment uptime: \u0026gt;98% (2024)\u003c\/li\u003e\n\u003cli\u003eContract value (2024): RMB 450M+\u003c\/li\u003e\n\u003cli\u003eRenewal rate: 87%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Chain Collaborations for Retail Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartnerships with China's top pharmacy chains (e.g., 2024 market leaders Yifeng Pharmacy and Guoda Drug; national retail pharmacy channel ~¥1.2 trillion) place Lepu's drugs and POCT kits in thousands of community outlets, raising access for chronic-disease patients at primary care level.\u003c\/p\u003e\n\u003cp\u003eThis retail footprint supports Lepu's shift to outpatient chronic care, complements hospital sales (2024 device revenue ~CNY 3.1 bn), and boosts consumer brand recognition among non-hospital users.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail reach: thousands of outlets via top chains\u003c\/li\u003e\n\u003cli\u003eMarket size: pharmacy retail ~¥1.2 trillion (2024)\u003c\/li\u003e\n\u003cli\u003eStrategic goal: primary-care chronic disease management\u003c\/li\u003e\n\u003cli\u003eBrand impact: greater recognition outside hospitals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLepu: 15k hospitals, 120+ countries, RMB450M contracts, 1.2M DTC shoppers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLepu’s place strategy combines 15,000 hospitals\/30,000 clinics domestic reach, 120+ country exports, 3 regional hubs (Beijing, Shanghai, Guangzhou), \u0026lt;24h on-site response, \u0026gt;98% uptime, RMB 450M+ multi-year contracts and 87% renewal (all 2024 figures), plus DTC e‑commerce (1.2M shoppers) and pharmacy chain presence driving outpatient chronic-care access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Clinics\u003c\/td\u003e\n\u003ctd\u003e15,000 \/ 30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport markets\u003c\/td\u003e\n\u003ctd\u003e120+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional hubs\u003c\/td\u003e\n\u003ctd\u003eBeijing, Shanghai, Guangzhou\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg response\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;24 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContracts value\u003c\/td\u003e\n\u003ctd\u003eRMB 450M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e87%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC shoppers\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eLepu Medical Technology (Beijing) Co. 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Lepu Medical Technology (Beijing) Co. 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises; it covers Product, Price, Place and Promotion with actionable insights tailored to the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750745321849,"sku":"lepumedical-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lepumedical-marketing-mix.png?v=1772226109","url":"https:\/\/matrixbcg.com\/products\/lepumedical-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}